Evidence map›Paper›PMID 22183962›Full record

ArticleArthritis and rheumatism2012

Methotrexate increases expression of cell cycle checkpoint genes via JNK activation.

Charles F Spurlock, John T Tossberg, Howard A Fuchs, Nancy J Olsen, Thomas M Aune

Abstract read
In one paragraph

Article in Arthritis and rheumatism, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Cells · 2024
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Effects of methotrexate exposure on medaka (Journal of toxicologic pathology · 2017
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Charles F SpurlockVanderbilt University School of Medicine, Nashville, TN, USA.
John T Tossberg
Howard A Fuchs
Nancy J Olsen
Thomas M Aune
Vanderbilt University · USPenn State Milton S. Hershey Medical Center · USVanderbilt University Medical Center · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
IFN GAMMA GENE REGULATION IN T CELLS AND NK CELLSR01AI044924 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI AUNE, THOMAS M. · 2000 to 2019
$5.8M
Gene Expression and Diagnosis of Autoimmune DiseaseR42AI053984 · NIAID · ARTHROCHIP, LLC · PI AUNE, THOMAS M. · 2004 to 2010
$3.4M
NCI NIH HHS P30 CA068485NCI NIH HHS P30-CA-68485NIAID NIH HHS R01 AI044924NIAID NIH HHS R01-AI-044924NIAID NIH HHS R42 AI053984NIAID NIH HHS R42-AI-53948NIDDK NIH HHS DK-058404NIDDK NIH HHS P30 DK058404
6 · The paper itself

Abstract

objectiveTo assess defects in expression of critical cell cycle checkpoint genes and proteins in patients with rheumatoid arthritis (RA) relative to presence or absence of methotrexate (MTX) treatment, and to investigate the role of JNK in induction of these genes by MTX.

methodsFlow cytometric analysis was used to quantify changes in levels of intracellular proteins, measure reactive oxygen species (ROS), and determine apoptosis in different lymphoid populations. Quantitative reverse transcription-polymerase chain reaction was used to identify changes in cell cycle checkpoint target genes.

resultsRA patients expressed reduced baseline levels of MAPK9, TP53, CDKN1A, CDKN1B, CHEK2, and RANGAP1 messenger RNA (mRNA) and JNK total protein. The reduction in expression of mRNA for MAPK9, TP53, CDKN1A, and CDKN1B was greater in patients not receiving MTX than in those receiving low-dose MTX, with no difference in expression levels of CHEK2 and RANGAP1 mRNA between MTX-treated and non-MTX-treated patients. Further, JNK levels were inversely correlated with C-reactive protein levels in RA patients. In tissue culture, MTX induced expression of both p53 and p21 by JNK-2- and JNK-1-dependent mechanisms, respectively, while CHEK2 and RANGAP1 were not induced by MTX. MTX also induced ROS production, JNK activation, and sensitivity to apoptosis in activated T cells. Supplementation with tetrahydrobiopterin blocked these MTX-mediated effects.

conclusionOur findings support the notion that MTX restores some, but not all, of the proteins contributing to cell cycle checkpoint deficiencies in RA T cells, via a JNK-dependent pathway.

Indexed as

AdultAgedAntirheumatic AgentsApoptosisArthritis, RheumatoidCell Cycle CheckpointsFemaleFlow CytometryHumansMaleMAP Kinase Signaling SystemMethotrexateMiddle AgedReactive Oxygen SpeciesAntirheumatic AgentsMethotrexateReactive Oxygen Species

Identifiers

PMID22183962
PMCPMC3310965
OpenAlexW2019430552

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.